Back to mobile site

Truist on Abivax (ABVX): 'We continue to see a robust opportunity'

March 24, 2026 9:01 AM EDT Send to a Friend
Truist Securities analyst Greg Renza reiterated a Buy rating and $140.00 price target on Abivax (NASDAQ: ABVX).The analyst commented: "Recent ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login